Toripalimab Combo Delivers Long-Term Efficacy in Nasopharyngeal Cancer | Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
Toripalimab Combo Delivers Long-Term Efficacy in Nasopharyngeal …
10 months ago
targetedonc.com
Initial Insights From JUPITER-02 - Toripalimab Efficacy in R/M NPC | OncLive
Initial Insights From JUPITER-02 - Toripalimab Efficacy in R/M NPC | …
7 months ago
onclive.com
Treatment Landscape of Recurrent NPC: Evaluating First-Line Toripalimab in the Recurrent Setting | Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
Treatment Landscape of Recurrent NPC: Evaluating First-Line Toripal…
11 months ago
targetedonc.com
Targeting Recurrent and Metastatic NPC With Systemic Immunotherapy: The Role of Toripalimab and Insights From Radiation Oncology | Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
Targeting Recurrent and Metastatic NPC With Systemic Immunotherap…
11 months ago
targetedonc.com
Proud to announce the launch of Toripalimab in India, the first and only immuno-oncology drug approved by various regulatory authorities around the world such as the USFDA, DCGI, EMA, MHRA and others for the treatment of adults with recurrent or metastatic nasopharyngeal carcinoma (RM-NPC). Toripalimab is a New Biological Entity (NBE). The combination of Toripalimab and standard of care chemotherapy has shown a 48% reduction in risk of progression or death, meeting a significant unmet need for p
0:18
Proud to announce the launch of Toripalimab in India, the first and …
194 viewsNov 28, 2024
FacebookDr. Reddy's Laboratories Ltd.
Phase II Trial Results of Disitamab Vedotin and Toripalimab Combination for Muscle-Invasive Bladder Cancer - Xinan Sheng
Phase II Trial Results of Disitamab Vedotin and Toripalimab Combina…
11 months ago
urotoday.com
Junshi Biosciences Announces Toripalimab's NDA Accepted by the Singapore Health Sciences Authority
Junshi Biosciences Announces Toripalimab's NDA Accepted by th…
Feb 2, 2024
finanznachrichten.de
Dr Yuan on 3-Year Data for Perioperative Toripalimab/Chemo …
1 month ago
onclive.com
Junshi Biosciences Announces Approval of sNDA for Toripalimab …
10 months ago
thespec.com
4:56
Subcutaneous Toripalimab: Promising NSCLC Treatment | No…
2 months ago
YouTubeThe Daily Wave
6:09
DIAMOND: toripalimab & radiotherapy in nasopharyngeal c…
326 views8 months ago
YouTubeVJOncology
5:28
What Is The Moa Of Loqtorzi Toripalimab
73 viewsJul 18, 2024
YouTubeRX Card Club
6:13
Toripalimab plus metronomic chemotherapy show efficacy in tre…
263 viewsFeb 20, 2024
YouTubeecancer
1:26
Toripalimab #How is it different
77 views4 months ago
YouTubeCancer education made simple # Chandrakant…
2:22
NEOTORCH Trial: Perioperative Toripalimab for NSCLC - OncTalk …
106 viewsApr 2, 2024
YouTubeGlobal Resource for Advancing Cancer Education
Toripalimab FLOT Regimen Improves Gastric Cancer Outcome…
19.9K views1 month ago
linkedin.com
Coherus BioSciences obtient l'examen prioritaire de la FDA pou…
6 months ago
zonebourse.com
3:23
Instagram
38.1K views5 months ago
Instagramthecancerdoctor10
4:12
Chidamide plus toripalimab shows promise in advanced sarcoma
66 views3 months ago
YouTubeVJOncology
4:58
Toripalimab plus chemotherapy improves 3-year survival in resect…
3 weeks ago
Vimeoecancer
5:40
ASCO 2026 update l Is Toripalimab the GAME CHANGER for Resectab…
463 views1 month ago
YouTubeEdusurg Clinics
1:33
RC48-C016: disitamab vedotin & toripalimab vs chemotherapy in H…
77 views3 months ago
YouTubeVJOncology
China’s new cancer drug Toripalimab is approved in the US …
Nov 29, 2023
South China Morning PostVictoria Bela
8:24
RENOTORCH Phase III: Toripalimab + Axitinib vs Sunitinib in Advance…
26 views5 months ago
YouTubeCancer Research and Statistic Foundation
2:52
कैंसर की नयी दवाई Immunotherapy for Head & Neck, …
3.1K viewsDec 17, 2024
YouTubeDr. Pratik Patil Oncologist
1:18:31
The Power and Promise of Immunotherapy in Head and Neck …
4.4K viewsJul 29, 2022
YouTubePeerView Oncology
topalliance-biosciences-inc_loqtorzi-toripalimab ...
Sep 25, 2024
linkedin.com
Surface Oncology : Coherus to Acquire Surface Oncology - Form …
Jun 16, 2023
marketscreener.com
6:10
FDA-approved Chinese cancer drug to cost 30 times more
Dec 12, 2023
South China Morning PostVictoria Bela, Nick Dearman
4:14
@uromigos on Instagram: "After the success of Disitamab Vedotin plu…
58 views3 months ago
Instagramuromigos
See more videos
Static thumbnail place holder